Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Nam-Jun | - |
dc.contributor.author | Jeong, Seung-Hyun | - |
dc.contributor.author | Lee, Ka Young | - |
dc.contributor.author | Yu, Jin Young | - |
dc.contributor.author | Park, Samel | - |
dc.contributor.author | Lee, Eun Young | - |
dc.contributor.author | Gil, Hyo-Wook | - |
dc.date.accessioned | 2022-05-03T01:40:37Z | - |
dc.date.available | 2022-05-03T01:40:37Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/20702 | - |
dc.description.abstract | Expanded hemodialysis (HD) equipped with a medium cut-off (MCO) membrane provides superior removal of larger middle molecules. However, there is still little research on the long-term benefits of expanded HD. Over a three-year period, this observational study evaluated the efficacy and safety profile of expanded HD for inflammatory cytokines, including IL-6. We conducted a prospective cohort study to investigate the inflammatory cytokine changes and a retrospective observational cohort study to investigate long-term clinical efficacy and safety over a three-year period. We categorized the patients according to dialyzer used: MCO and high-flux (HF) dialyzer. The inflammatory cytokines, including IFN-gamma, IL-1 beta, IL-6, and TNF-alpha, were measured annually. The concentrations and changes of the four cytokines over time did not differ between the HF group (n = 15) and MCO group (n = 27). In both prospective and retrospective (HF group, n = 38; MCO group, n = 76) cohorts, there were no significant differences in either death, cardiovascular events, infections, or hospitalizations. Furthermore, the temporal changes in laboratory values, including serum albumin and erythropoietin prescriptions, did not differ significantly between the two groups in either the prospective or retrospective cohorts. In conclusion, clinical efficacy and safety outcomes, as well as inflammatory cytokines, did not differ with expanded HD compared with HF dialysis during a three-year treatment course, although the level of inflammatory cytokine was stable. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI AG | - |
dc.title | Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/jcm11082261 | - |
dc.identifier.scopusid | 2-s2.0-85128564801 | - |
dc.identifier.wosid | 000785670400001 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Medicine, v.11, no.8, pp 1 - 11 | - |
dc.citation.title | Journal of Clinical Medicine | - |
dc.citation.volume | 11 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | MEDIUM CUTOFF | - |
dc.subject.keywordPlus | INTERLEUKIN-6 | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | MEMBRANES | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordAuthor | cytokines | - |
dc.subject.keywordAuthor | interleukin-6 | - |
dc.subject.keywordAuthor | expanded hemodialysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.